RxDoctor Payments Data

Lara Jaber, MD

Family Medicine · Highland, CANPI 1548767031

Payments from drug & device makers

$651in general payments, 2019–2025

Across 36 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$237
  • Novo Nordisk$97
  • Biohaven Pharmaceutical Holding Company Ltd.$60
  • Pfizer$51
  • AbbVie$47
  • Kowa Pharmaceuticals America, Inc.$44
  • plus $114 from 5 others

What the payments were for

  • Food & beverage$651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$651 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$12,101
Medicare patients
55
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$70,755
JanuviaSitagliptin Phosphate35$43,585
OzempicSemaglutide35$41,288
EliquisApixaban31$37,218
TrulicityDulaglutide17$18,815
XareltoRivaroxaban12$16,295
MounjaroTirzepatide14$16,090
FarxigaDapagliflozin Propanediol12$10,785
TrintellixVortioxetine Hydrobromide15$10,639
Wixela InhubFluticasone Propion/Salmeterol31$8,652
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$8,649
Spiriva HandihalerTiotropium Bromide11$7,408
Atorvastatin Calcium517$5,171
Albuterol Sulfate HfaAlbuterol Sulfate163$4,303
Gabapentin155$3,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$31$70,75568 claims
Novo NordiskOzempic$97$41,28835 claims
PfizerEliquis$51$37,21831 claims
Lilly USA, LLCTrulicity, Mounjaro$237$34,90531 claims
AstraZenecaFarxiga$14$10,78512 claims
AbbVieSynthroid$47$1,56632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Highland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →